Your browser doesn't support javascript.
loading
Reductions in vancomycin and meropenem following the implementation of a febrile neutropenia management algorithm in hospitalized adults: An interrupted time series analysis.
Trinh, Trang D; Strnad, Luke; Damon, Lloyd; Dzundza, John H; Graff, Larissa R; Griffith, Laura M; Hilts-Horeczko, Alexandra; Olin, Rebecca; Shenoy, Samantha; DeVoe, Catherine; Wang, Lusha; Rodriguez-Monguio, Rosa; Gu, Tina M; Hampton, Scott R; Macapinlac, Brian Allan C; Yang, Katherine; Doernberg, Sarah B.
Afiliação
  • Trinh TD; Medication Outcomes Center, Department of Clinical Pharmacy, University of California, San Francisco School of Pharmacy, San Francisco, California.
  • Strnad L; Division of Infectious Diseases, Department of Medicine, Oregon Health and Sciences University School of Medicine, Portland, Oregon.
  • Damon L; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco School of Medicine, San Francisco, California.
  • Dzundza JH; Division of Hospital Medicine, Department of Medicine, University of California, San Francisco School of Medicine, San Francisco, California.
  • Graff LR; Department of Pharmaceutical Services, University of California, San Francisco Health, San Francisco, California.
  • Griffith LM; Department of Nursing, University of California, San Francisco Health, San Francisco, California.
  • Hilts-Horeczko A; Department of Pharmaceutical Services, University of California, San Francisco Health, San Francisco, California.
  • Olin R; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco School of Medicine, San Francisco, California.
  • Shenoy S; Hematology and Oncology Clinic, University of California, San Francisco Health, San Francisco, California.
  • DeVoe C; Division of Infectious Diseases, Department of Medicine, University of California School of Medicine, San Francisco, San Francisco, California.
  • Wang L; Division of Infection Prevention, Department of Quality, University of California, San Francisco Health, San Francisco, California.
  • Rodriguez-Monguio R; Medication Outcomes Center, Department of Clinical Pharmacy, University of California, San Francisco School of Pharmacy, San Francisco, California.
  • Gu TM; Department of Pharmaceutical Services, University of California, San Francisco Health, San Francisco, California.
  • Hampton SR; Department of Pharmacy, University of California, San Diego Health, San Diego, California.
  • Macapinlac BAC; Department of Pharmacy, Kaiser Permanente, Union City, California.
  • Yang K; Department of Clinical Pharmacy, University of California, San Francisco School of Pharmacy, San Francisco, California.
  • Doernberg SB; Division of Infectious Diseases, Department of Medicine, University of California School of Medicine, San Francisco, San Francisco, California.
Infect Control Hosp Epidemiol ; 42(9): 1090-1097, 2021 09.
Article em En | MEDLINE | ID: mdl-33487182
ABSTRACT

OBJECTIVE:

To evaluate broad-spectrum intravenous antibiotic use before and after the implementation of a revised febrile neutropenia management algorithm in a population of adults with hematologic malignancies.

DESIGN:

Quasi-experimental study. SETTING AND POPULATION Patients admitted between 2014 and 2018 to the Adult Malignant Hematology service of an acute-care hospital in the United States.

METHODS:

Aggregate data for adult malignant hematology service were obtained for population-level antibiotic use days of therapy (DOT), C. difficile infections, bacterial bloodstream infections, intensive care unit (ICU) length of stay, and in-hospital mortality. All rates are reported per 1,000 patient days before the implementation of an febrile neutropenia management algorithm (July 2014-May 2016) and after the intervention (June 2016-December 2018). These data were compared using interrupted time series analysis.

RESULTS:

In total, 2,014 patients comprised 6,788 encounters and 89,612 patient days during the study period. Broad-spectrum intravenous (IV) antibiotic use decreased by 5.7% with immediate reductions in meropenem and vancomycin use by 22 (P = .02) and 15 (P = .001) DOT per 1,000 patient days, respectively. Bacterial bloodstream infection rates significantly increased following algorithm implementation. No differences were observed in the use of other antibiotics or safety outcomes including C. difficile infection, ICU length of stay, and in-hospital mortality.

CONCLUSIONS:

Reductions in vancomycin and meropenem were observed following the implementation of a more stringent febrile neutropenia management algorithm, without evidence of adverse outcomes. Successful implementation occurred through a collaborative effort and continues to be a core reinforcement strategy at our institution. Future studies evaluating patient-level data may identify further stewardship opportunities in this population.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Clostridioides difficile / Neutropenia Febril Tipo de estudo: Prognostic_studies Limite: Adult / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Clostridioides difficile / Neutropenia Febril Tipo de estudo: Prognostic_studies Limite: Adult / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article